Navigation Links
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/30/2008

ovac sold 0.52 million doses of Anflu(R), which accounted for 27% of quarterly sales. Sinovac is co-marketing Anflu(R) with GSK China and recently launched an extensive marketing campaign. Seasonal influenza vaccine sales to CDCs typically occur during third quarter, subject to seasonality as people get vaccinated from the end of the third quarter to the beginning of the fourth quarter.

Research and Development

In April 2007, Sinovac was granted approval by the China State Food and Drug Administration (SFDA) to enter into Phase II clinical trials for Panflu, the Company's pandemic influenza vaccine (H5N1). The SFDA approval covered Phase Ib and Phase II trials of the whole viron vaccine and Phase I and Phase II trials of the split vaccine.

In December 2007, Sinovac reported positive top-line results of completed Phase II clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine. The randomized, double-blind trial of the vaccine was designed to assess the safety and immunogenicity of the vaccine. The study included 402 volunteers, between the ages of 18 and 60, who were each vaccinated with two doses of 5 ug, 10 ug or 15 ug. The preliminary results of the trials suggested that each of the three dosages may induce varying degrees of immune response. In February 2008, the report with results from the Phase II trial of the whole viron inactivated vaccine was submitted for review to the SFDA.

In 2007, Sinovac initiated a co-development project with National Institute for Viral Disease Control and Prevention, China CDC to develop a universal pandemic influenza vaccine to against pandemic flu caused by unknown flu viruses. It's in pre-clinical trial and we expect to file a clinical trial application in 2010.

Conference Call Details

The Company will hold a conference call on Monday, March 31, 2008 at 9:00 a.m. ET (9:00 p.m. Beijing time). The conference call dial-in numbers are 1- 877-407-4018 (USA) or 1-201-68
'/>"/>

SOURCE Sinovac Biotech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... It is now possible to separate two common disorders: post-traumatic stress disorder ... according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and University of ... to be the largest brain imaging study ever, will be published on July 1, ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, David ... , The presentation took place on Tuesday, June 16 and provided an ... of APX3330 for the treatment of pancreatic cancer. A copy of the company ...
(Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... FORT LAUDERDALE, Fla., Aug. 13 OmniComm Systems, ... data capture (EDC) solutions for clinical trials, today announced that ... Research Organization (CRO) to provide eClinical solutions for a pivotal ... studies serve to establish the safety and efficacy of investigational ...
... , ANNAPOLIS, Md., Aug. 13 PharmAthene, ... medical countermeasures against biological and chemical threats, today reported financial and ... 30, 2009. , , For the second quarter ... million in the same period of 2008. For the six ...
... CHENGDU, China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., ... and supplier of,modernized traditional Chinese medicine ("TCM") based in ... the Chinese State Food and Drug,Administration (SFDA) to produce ... number Z20093512) and Yinqiao Jiedu Tablets in,dosage form of ...
Cached Biology Technology:Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
(Date:6/15/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces that its leading payment security technology, the ... Experience! @ NYC June 18th. Digital Experience! @ ... in technology to over 300 of the top media covering ... Pavilion in New York City from ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... moths can hear the ultrasonic hunting calls of their nocturnal ... the insect world—they have only two or four vibration-sensitive neurons ... these ears were only partially sensitive to the sound frequencies ... by using high ultrasound, bats would make their hunting calls ...
... response against HIV, research funded by the Wellcome Trust in ... US has found that bigger is not necessarily better, contrary ... impact on the development of a vaccine against the disease. ... immune response, the more effective it will be in controlling ...
... related species of green algae that practice different forms ... route by which evolution gave rise to reproduction though ... findings, which indicate that a gene underlying a more ... to participate in sex-specific sperm development, are reported by ...
Cached Biology News:Quality not quantity important for immune response to HIV 2A new male-specific gene in algae unveils an origin of male and female 2
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: